,,ii #aahth ,,congress #b;d ,session ,s4 #ddbi ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,may #bc1 #bjbd,mr4 ,booker 7for himself1 ,mr4 ,braun1 and ,mr4 ,markey7 introduced the following bill2 which was read twice and referred to the ,committee on ,health1 ,education1 ,labor1 and ,pensions ,a ,,bill ,to require the ,secretary of ,health and ,human ,services to provide grants to demonstrate pharmacy-based addiction care programs4 #a4 ,short title ,this ,act may be cited as the ,substance ,use ,prevention and ,pharmacy ,oriented ,recovery ,treatment ,prescription ,act or the ,,support ,rx ,act4 #b4 ,pharmacy-based addiction care demonstration program 7a7 ,in general ,the ,secretary of ,health and ,human ,services 7referred to in this section as the ,secretary7 shall carry out a #c-year demonstration program under which the ,secretary shall award grants to eligible entities to establish1 maintain1 or improve a pharmacy-based addiction care program4 7b7 ,eligibility ,to be eligible to receive a grant under subsection 7a71 an entity shall be-- 7#a7 a ,state1 ,tribal1 or local health department2 7#b7 a partnership between such a health department and #a or more other public entities or private entities located in a ,state1 the laws of which allow pharmacists to prescribe1 or enter into collaborative practice agreements with physicians authorized to prescribe1 a controlled substance that is listed on schedule ,,iii of section #bjb7;c7 of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hab7;c772 or 7#c7 a specialty addiction treatment practitioner in a primary care setting or a specialty substance use disorder treatment facility4 7c7 ,applications ,an eligible entity desiring a grant under subsection 7a7 shall submit to the ,secretary an application at such time1 in such manner1 and containing such information as the ,secretary may require1 including-- 7#a7 a plan to establish a collaborative practice agreement-- 7,a7 through which board certified addiction medicine physicians or addiction psychiatrists shall collaborate with pharmacists permitted to enter into such agreements under applicable ,state law in order to enable such pharmacists to provide drug therapy management2 and 7,b7 under which the prescriptive authority of a pharmacist shall not exceed the authority that is specified in the collaborative practice agreement2 7#b7 a description of activities proposed to be carried out pursuant to the grant2 and 7#c7 a plan to sustain activities described in such application following the conclusion of the grant period4 7d7 ,use of funds 7#a7 ,in general ,an eligible entity receiving a grant under subsection 7a7 shall use the grant funds to establish1 maintain1 or improve a comprehensive1 pharmacy-based addiction care program to support withdrawal1 induction1 ongoing care1 and rescue for individuals with opioid or other substance use disorders1 provided by and at community pharmacies1 including by-- 7,a7 offering buprenorphine for opioid and other substance use disorders1 and managing withdrawal from opioids and other substances when appropriate1 induction1 and maintenance care2 7,b7 rendering same-day care services of low-barrier treatment1 with no or reduced requirements1 including no or reduced requirements for payment1 insurance1 age limits 7to the extent authorized under ,state or ,federal law71 and identification2 and 7,c7 training pharmacists on treating and managing patients with opioid and other substance use disorders1 which training1 at a minimum1 shall be in accordance with paragraph 7#a77;,b7 of the second subsection 7l7 of section #cjc of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hbc7 7as added by section #abfc7;a7 of the ,consolidated ,appropriations ,act1 #bjbc 7,public ,law #aag-cbh2 #acf ,stat4 #efhc774 7#b7 ,additional uses ,in addition to uses described in paragraph 7#a71 an eligible entity receiving a grant under subsection 7a7 shall use the grant funds-- 7,a7 to provide compensation to staff for pharmacy program and other program operations for which the staff would not otherwise receive compensation2 7,b7 to provide payment for an individual to obtain not more than a #cj-;day supply of buprenorphine prescribed at any one time under the pharmacy-based addiction care program supported by the grant2 7,c7 to provide care continuity fee payments to providers or clinics the patients of which transfer their maintenance care to the pharmacy-based addiction care program supported by the grant to support good recordkeeping1 safe transfer1 and transition in care2 7,d7 to provide telebehavioral health services2 7,e7 to provide construction to permit private or semi-private spaces for counseling and administration of medication2 7,f7 to provide secure technology that is in compliance with ,,hipaa privacy regulations1 as defined in section #aahj7;b77#c7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acbj;d-#i7;b77#c772 7,g7 to establish a collaborative practice agreement described in subsection 7c77#a72 7,h7 to pay for the costs of training staff in administration of opioid reversal medications approved by the ,food and ,drug ,administration2 7,i7 to pay for other necessary staff training1 including the training described in paragraph 7#a77;,c72 and 7,j7 to pay for registration fees in each applicable ,state in accordance with section #cjb7;e7 of the ,controlled ,substances ,act 7#ba ,u4,s4,c4 #hbb7;e774 7#c7 ,limitation ,no funds made available under a grant under subsection 7a7 may be used to prescribe or dispense any drug other than buprenorphine or an opioid overdose reversal drug4 7e7 ,pharmacy-,based addiction care guidance ,not later than #ahj days after the date of enactment of this ,act1 the ,secretary shall issue guidance to provide eligible entities and pharmacists with technical assistance1 recommendations1 and best practices regarding treatment to support management of withdrawal from opioids and other substances when appropriate1 induction1 ongoing care1 and rescue4 7f7 ,report to the ,secretary ,each recipient of a grant under subsection 7a7 shall submit to the ,secretary an annual evaluation of the progress of the pharmacy-based addiction care program supported by the grant1 including information on-- 7#a7 the number of patients receiving treatment2 7#b7 any changes in local rates of overdose over the course of the grant2 and 7#c7 any other readily available information the ,secretary determines necessary1 including-- 7,a7 cost data2 7,b7 patient-reported outcomes2 7,c7 overdose data2 7,d7 hospitalization data2 7,e7 quality and safety measures2 7,f7 program retention data2 7,g7 data on the opioid prescriptions fill rates2 7,h7 the demographic characteristics of patients who were treated by the program2 and 7,i7 any other information the ,secretary determines necessary4 7g7 ,report to ,congress ,not later than #abj days after completion of the demonstration program under this section1 the ,secretary shall submit to ,congress a report that describes the results of the demonstration program1 including-- 7#a7 the number of applications received for grants under the demonstration program1 and the number of grants awarded2 7#b7 a summary of the evaluations submitted under subsection 7f71 including standardized data2 and 7#c7 recommendations for broader implementation of pharmacy-based addiction models of care4 7h7 ,funding ,the ,secretary shall carry out the demonstration program under this section using amounts available to the ,secretary1 and not otherwise obligated1 for the ,harm ,reduction ,grant ,program of the ,substance ,abuse and ,mental ,health ,services ,administration pursuant to section #eaf7;a7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bij;bb-#bb7;a77 and section #bgjf of the ,american ,rescue ,plan ,act of #bjba 7#db ,u4,s4,c4 #bij;dd-#c note2 ,public ,law #aag-b74